A Study of RD06-04 in Patients With Active Autoimmune Diseases (NCT06548620) | Clinical Trial Compass
WithdrawnEarly Phase 1
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Stopped: R\&D strategy adjustment
China0Started 2024-08-31
Plain-language summary
This is an open-label, Phase I, investigator-initiated trial (IIT) aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with autoimmune diseases mediated by autoantibodies. The study population includes patients with Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM), Sjögren's Syndrome (SS), Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and Myasthenia Gravis (MG).
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The subjects voluntarily participated in the study and signed the informed consent form.
✓. Age ≥18 years old and ≤70 years old, both sexes.
✓. Organ function and laboratory tests:
✓. Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3× upper limit of normal (ULN), total bilirubin (TBIL) ≤2×ULN (except Gilbert's syndrome).
✓. Renal function: creatinine ≤1.5×ULN or creatinine clearance ≥40 ml/min.
✓. Coagulation: international normalized ratio (INR) ≤ 1.5×ULN, or prothrombin time (PT) ≤ 1.5×ULN.
✓. Oxygen saturation (SpO2) ≥92% at rest in room air.
Exclusion criteria
✕. SLE Patients: Those with uncontrolled lupus crisis within the 8 weeks prior to screening, including rapidly progressive lupus nephritis, severe neuropsychiatric lupus, severe hemolytic anemia, severe immune thrombocytopenia, agranulocytosis, severe cardiac damage, severe lupus pneumonia, severe lupus hepatitis, and severe vasculitis, as assessed by the investigator as unsuitable to participate in this study.
What they're measuring
1
Incidence of treatment-emergent adverse events, serious adverse events and incidence of adverse events of special inte rest
✕. IIM Patients: Presence of severe rhabdomyolysis or CK levels ≥120×ULN at screening.
✕. MG Patients: Presence of uncontrolled myasthenia gravis crisis within 2 weeks prior to screening.
✕. Patients with severe asthma or Chronic Obstructive Pulmonary Disease (COPD) are eligible. Patients with mild or moderate asthma or COPD who are receiving stable treatment can also be enrolled.
✕. There has been an active infection requiring systemic treatment within 2 weeks prior to the urethral irrigation, such as infectious pneumonia, tuberculosis, etc.
✕. Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA in peripheral blood; positive for hepatitis C virus (HCV) antibody with detectable HCV RNA in peripheral blood; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis antibody.
✕. Pregnant or breastfeeding women.
✕. Any condition that, in the investigator's opinion, may affect study participation, pose a safety risk to the patient, or potentially confound the interpretation of study results.